Semaglutide

FDA ApprovedStrong Evidence
Written by dr-sarah-chen|Reviewed by Healthier Rx Editorial Board|Updated 2026-04-01|4 min read
Quick Facts
TypeGLP-1 / Weight Loss
FDA StatusFDA Approved
Evidence LevelStrong Evidence
Typical Dose0.25-2.4mg/week
FrequencyOnce weekly
Cycle LengthOngoing
Key GoalsWeight Loss, Metabolic Health, Cardiovascular Protection

How It Works

Semaglutide is a synthetic version of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut after eating.

When you eat, natural GLP-1 is released to stimulate insulin production and tell your brain you are full. However, natural GLP-1 breaks down in the body within minutes. Semaglutide is structurally modified to resist this breakdown, giving it a half-life of roughly seven days for once-weekly dosing.

Semaglutide operates through three primary mechanisms:

  1. Neurological: It crosses the blood-brain barrier and binds to receptors in the hypothalamus, directly reducing appetite and cravings (often referred to as "food noise").
  2. Gastrointestinal: It delays gastric emptying. Food stays in your stomach longer, physically keeping you full.
  3. Metabolic: It stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner, stabilizing blood sugar levels.

Benefits

  • Average 14.9-15.3% body weight loss in STEP trials (2.4mg dose, 68 weeks)
  • 20% reduction in major cardiovascular events (SELECT trial) — proven heart protection
  • Significant improvements in insulin sensitivity and HbA1c
  • Reduction in systemic inflammation (CRP)
  • Available in both injectable and oral (Rybelsus) formulations
  • The most long-term safety data of any GLP-1 agonist

Side Effects

  • Nausea (most common, affecting up to 44% of users, peaks 24-48 hours after injection)
  • Fatigue (often a byproduct of reduced caloric intake)
  • Constipation or diarrhea (altered gastric emptying)
  • Acid reflux (if eating large or high-fat meals)
  • Injection site reactions (mild)

Dosing Protocol

PhaseDurationWeekly DosePurpose
InitiationWeeks 1-40.25mgAcclimate the body, minimize nausea
Step 1Weeks 5-80.5mgBegin therapeutic escalation
Step 2Weeks 9-121.0mgFirst significant clinical dose
Step 3Weeks 13-161.7mgTransition to maintenance
MaintenanceWeek 17+2.4mgMaximum therapeutic dose

Many patients achieve their target weight loss at 1.0mg or 1.7mg and do not need to escalate to 2.4mg. Dosing should always be guided by clinical response and side effect tolerance.

What You Will Need

  • Semaglutide prescription (via telehealth clinic, endocrinologist, or PCP)
  • Pre-filled injection pens (brand Wegovy/Ozempic) or compounded vials with insulin syringes
  • Alcohol swabs
  • Sharps container

Mitigating Side Effects

  • Stay hydrated: Drink significantly more water than usual
  • Prioritize protein: Focus on high-protein, nutrient-dense foods to preserve lean muscle
  • Eat smaller meals: Because the stomach empties slower, large meals cause severe discomfort
  • Do not rush titration: If you experience severe nausea at 0.5mg, do not move up to 1.0mg until it subsides
  • Resistance training: Essential to prevent muscle loss during rapid weight loss

Frequently Asked Questions

References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)New England Journal of Medicine (2021). PMID: 33567185

    Landmark trial showing 14.9% average weight loss at 68 weeks with semaglutide 2.4mg in adults with overweight or obesity.

  2. Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)New England Journal of Medicine (2023). PMID: 37952131

    Proved semaglutide reduces major cardiovascular events by 20% in high-risk patients with overweight or obesity.

Compare Semaglutide

Related Goals

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or protocol. Read our full medical disclaimer.